Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Presbycusis | 8 | 2017 | 12 | 1.570 |
Why?
|
| Temporal Bone | 10 | 2014 | 61 | 1.410 |
Why?
|
| Spiral Ganglion | 9 | 2017 | 25 | 1.080 |
Why?
|
| Cochlea | 7 | 2017 | 50 | 0.800 |
Why?
|
| Aging | 3 | 2017 | 766 | 0.650 |
Why?
|
| Otosclerosis | 2 | 2014 | 4 | 0.640 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 417 | 0.520 |
Why?
|
| Vestibular Nerve | 1 | 2017 | 33 | 0.510 |
Why?
|
| Goldfish | 1 | 2016 | 6 | 0.500 |
Why?
|
| Vitellogenins | 1 | 2016 | 10 | 0.500 |
Why?
|
| Taxoids | 1 | 2016 | 129 | 0.490 |
Why?
|
| Protein Precursors | 1 | 2016 | 138 | 0.490 |
Why?
|
| Hydroxycholesterols | 1 | 2016 | 6 | 0.480 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2016 | 34 | 0.470 |
Why?
|
| Biological Assay | 1 | 2016 | 84 | 0.470 |
Why?
|
| Cadherins | 1 | 2016 | 179 | 0.460 |
Why?
|
| Stria Vascularis | 2 | 2006 | 5 | 0.460 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 155 | 0.450 |
Why?
|
| Collagen Type I | 2 | 2014 | 74 | 0.430 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 4 | 0.430 |
Why?
|
| Chondroitin Sulfates | 1 | 2014 | 43 | 0.420 |
Why?
|
| Cholesterol | 1 | 2016 | 367 | 0.420 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 190 | 0.410 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 352 | 0.410 |
Why?
|
| Cell Membrane | 1 | 2016 | 687 | 0.410 |
Why?
|
| Cell Movement | 1 | 2016 | 816 | 0.390 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 3155 | 0.360 |
Why?
|
| Cochlear Nucleus | 1 | 2011 | 6 | 0.360 |
Why?
|
| DNA, Mitochondrial | 5 | 2011 | 200 | 0.360 |
Why?
|
| Liver | 1 | 2016 | 1231 | 0.350 |
Why?
|
| Cellular Senescence | 1 | 2011 | 106 | 0.340 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2004 | 52 | 0.320 |
Why?
|
| Obesity | 2 | 2016 | 1029 | 0.300 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1670 | 0.270 |
Why?
|
| Hair Cells, Vestibular | 1 | 2005 | 18 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2385 | 0.230 |
Why?
|
| Audiometry | 4 | 2011 | 14 | 0.220 |
Why?
|
| RNA Interference | 2 | 2016 | 385 | 0.220 |
Why?
|
| Cell Death | 3 | 2016 | 264 | 0.210 |
Why?
|
| Female | 15 | 2017 | 49980 | 0.210 |
Why?
|
| Microdissection | 4 | 2011 | 18 | 0.200 |
Why?
|
| Hair Cells, Auditory | 3 | 2017 | 26 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1827 | 0.190 |
Why?
|
| Cochlear Nerve | 1 | 2001 | 9 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 326 | 0.170 |
Why?
|
| Humans | 25 | 2017 | 95992 | 0.160 |
Why?
|
| Organ of Corti | 3 | 2006 | 10 | 0.160 |
Why?
|
| Male | 13 | 2017 | 45792 | 0.150 |
Why?
|
| Collodion | 2 | 2008 | 7 | 0.140 |
Why?
|
| Sequence Deletion | 2 | 2010 | 212 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2011 | 358 | 0.140 |
Why?
|
| Aged | 11 | 2017 | 20927 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2014 | 10307 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 897 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 7224 | 0.130 |
Why?
|
| Cell Count | 1 | 2017 | 202 | 0.130 |
Why?
|
| Hearing | 1 | 2017 | 64 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 215 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2016 | 279 | 0.120 |
Why?
|
| Lasers | 3 | 2011 | 102 | 0.120 |
Why?
|
| Lead | 1 | 2016 | 32 | 0.120 |
Why?
|
| Estrogen Antagonists | 1 | 2016 | 48 | 0.120 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2016 | 160 | 0.120 |
Why?
|
| Crime | 1 | 2016 | 38 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 120 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 286 | 0.120 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 56 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2016 | 322 | 0.110 |
Why?
|
| Workflow | 1 | 2016 | 80 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 345 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 528 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 517 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 579 | 0.110 |
Why?
|
| Middle Aged | 9 | 2014 | 28299 | 0.110 |
Why?
|
| Atrophy | 2 | 2006 | 131 | 0.110 |
Why?
|
| Triiodothyronine | 1 | 2016 | 362 | 0.110 |
Why?
|
| Ligands | 1 | 2016 | 478 | 0.110 |
Why?
|
| Age Factors | 2 | 2011 | 1959 | 0.110 |
Why?
|
| Transfection | 1 | 2016 | 908 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2016 | 740 | 0.100 |
Why?
|
| Reference Values | 2 | 2011 | 675 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 449 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1966 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2776 | 0.100 |
Why?
|
| Tissue Embedding | 2 | 2011 | 6 | 0.090 |
Why?
|
| Adult | 9 | 2011 | 28636 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 930 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 127 | 0.090 |
Why?
|
| Skull Neoplasms | 1 | 1991 | 27 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2011 | 126 | 0.080 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 2010 | 3 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 205 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2088 | 0.080 |
Why?
|
| Child | 5 | 2016 | 7621 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 159 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1347 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2011 | 1962 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 5593 | 0.070 |
Why?
|
| Stapes Surgery | 1 | 1989 | 6 | 0.070 |
Why?
|
| Cadaver | 2 | 2011 | 204 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 345 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 223 | 0.070 |
Why?
|
| Proteomics | 1 | 2010 | 268 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 24 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 124 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 310 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2008 | 65 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1982 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2008 | 276 | 0.060 |
Why?
|
| Animals | 2 | 2016 | 28901 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2042 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2016 | 3969 | 0.060 |
Why?
|
| Adolescent | 4 | 2011 | 9878 | 0.060 |
Why?
|
| Risk Factors | 1 | 2016 | 5992 | 0.060 |
Why?
|
| Linear Models | 1 | 2006 | 438 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 231 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1191 | 0.050 |
Why?
|
| Citalopram | 1 | 2003 | 21 | 0.050 |
Why?
|
| Neurons | 1 | 2011 | 1654 | 0.050 |
Why?
|
| Bulimia | 1 | 2003 | 144 | 0.050 |
Why?
|
| Tobramycin | 1 | 2001 | 5 | 0.040 |
Why?
|
| Gentamicins | 1 | 2001 | 21 | 0.040 |
Why?
|
| Deafness | 1 | 2001 | 48 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1756 | 0.040 |
Why?
|
| Cochlear Implantation | 1 | 2001 | 34 | 0.040 |
Why?
|
| Young Adult | 1 | 2011 | 7034 | 0.040 |
Why?
|
| Electron Transport Complex IV | 2 | 2008 | 49 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 819 | 0.030 |
Why?
|
| Missouri | 1 | 2016 | 19 | 0.030 |
Why?
|
| Cities | 1 | 2016 | 57 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 356 | 0.020 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2011 | 36 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2011 | 71 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Petrous Bone | 1 | 1991 | 10 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 89 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 86 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 857 | 0.020 |
Why?
|
| Ear, Middle | 1 | 1991 | 26 | 0.020 |
Why?
|
| Fixatives | 1 | 2010 | 12 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 40 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 212 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 163 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2010 | 53 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 150 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 364 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 90 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2611 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2009 | 16 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 562 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 296 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 317 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 280 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3359 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 313 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 337 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 684 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 548 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 611 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 2341 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 15 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 3040 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 3993 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2003 | 227 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2885 | 0.010 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2001 | 29 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1810 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 245 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3581 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 816 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 4374 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 789 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1792 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 2860 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 2605 | 0.010 |
Why?
|